Abstract
Progress in the field of NK cell receptors (NKRs) and their ligands has revolutionized our concept of how NK cells selectively recognize and lyse tumor while sparing normal cells. Major families of NKRs that inhibit and activate NK cells to lyse target cells have been characterized, including killer cell immunoglobulin-like receptors (KIRs), C-type lectins, and natural cytotoxicity receptors. Identification of NK receptor ligands such as HLA, MHC class I chain-related genes A and B – MICA/B, etc. further clarifies the role of NKR/ligand interactions in NK cell function. Given the extensive genomic diversity of KIRs, HLA and MIC, it is reasonable to imagine that genotypes encoding imbalanced inhibitory and activating interactions may contribute to susceptibility or resistance to human diseases, including cancers. This review will discuss two cell-surface receptor/ligand systems involved in NK cell recognition of tumor targets – KIR/HLA and NKG2D/MIC and the potential relevance of their genetic polymorphism in malignancies.
Keywords: NK cell receptors, NK receptor ligands, polymorphism, malignancies
Current Cancer Therapy Reviews
Title: NK Cell Receptor and MHC Gene Polymorphisms, Potential Relevance in Malignancies
Volume: 4 Issue: 2
Author(s): Anastassia Mihaylova, Snejina Mihailova and Elissaveta Naumova
Affiliation:
Keywords: NK cell receptors, NK receptor ligands, polymorphism, malignancies
Abstract: Progress in the field of NK cell receptors (NKRs) and their ligands has revolutionized our concept of how NK cells selectively recognize and lyse tumor while sparing normal cells. Major families of NKRs that inhibit and activate NK cells to lyse target cells have been characterized, including killer cell immunoglobulin-like receptors (KIRs), C-type lectins, and natural cytotoxicity receptors. Identification of NK receptor ligands such as HLA, MHC class I chain-related genes A and B – MICA/B, etc. further clarifies the role of NKR/ligand interactions in NK cell function. Given the extensive genomic diversity of KIRs, HLA and MIC, it is reasonable to imagine that genotypes encoding imbalanced inhibitory and activating interactions may contribute to susceptibility or resistance to human diseases, including cancers. This review will discuss two cell-surface receptor/ligand systems involved in NK cell recognition of tumor targets – KIR/HLA and NKG2D/MIC and the potential relevance of their genetic polymorphism in malignancies.
Export Options
About this article
Cite this article as:
Mihaylova Anastassia, Mihailova Snejina and Naumova Elissaveta, NK Cell Receptor and MHC Gene Polymorphisms, Potential Relevance in Malignancies, Current Cancer Therapy Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339408784310070
DOI https://dx.doi.org/10.2174/157339408784310070 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Multitarget Hybrid Compounds for the Treatment of Alzheimer’s Disease
Current Topics in Medicinal Chemistry “What Is And What Should Never Be”<sup>#</sup>: Use and Misuse of HPV Testing in Cervical Cancer Prevention Strategies
Current Women`s Health Reviews miR-629-3p Level Significantly Predicts Prognosis in Glioblastoma Patients Treated with Temozolomide Chemotherapy
Current Signal Transduction Therapy Photoprotective Carotenoids Lutein and Zeaxanthin: Their Role in AMD
Current Nutrition & Food Science Anticancer Perspectives on the Fungal-Derived Polyphenolic Hispolon
Anti-Cancer Agents in Medicinal Chemistry Beyond Stressed Self: Evidence for NKG2D Ligand Expression on Healthy Cells
Current Immunology Reviews (Discontinued) Noteworthy Secondary Metabolites Naphthoquinones – their Occurrence, Pharmacological Properties and Analysis
Current Pharmaceutical Analysis Biology of PPARγ in Cancer: A Critical Review on Existing Lacunae
Current Molecular Medicine Advances in Research on the Preparation and Biological Activity of Maslinic Acid
Mini-Reviews in Medicinal Chemistry Is HIV Involved in the Pathogenesis of Non-Infectious Pulmonary Complications in Infected Patients?
Current HIV Research An Update on Developments in Female Hormonal Contraception
Current Women`s Health Reviews Src Kinase Inhibitors: An Update on Patented Compounds
Current Medicinal Chemistry The Role of XRCC4 in Carcinogenesis and Anticancer Drug Discovery
Recent Patents on Anti-Cancer Drug Discovery Design, Synthesis and Biological Evaluation of Novel 1,2,5-Oxadiazol-3- Carboximidamide Derivatives as Indoleamine 2, 3-Dioxygenase 1 (IDO1) Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Neurotrophic Factors for the Investigation and Treatment of Movement Disorders
Current Medicinal Chemistry - Central Nervous System Agents Hybrid Compounds & Oxidative Stress Induced Apoptosis in Cancer Therapy
Current Medicinal Chemistry Synthetic and Natural Coumarins as Cytotoxic Agents
Current Medicinal Chemistry - Anti-Cancer Agents Persistent Current Blockers of Voltage-Gated Sodium Channels: A Clinical Opportunity for Controlling Metastatic Disease
Recent Patents on Anti-Cancer Drug Discovery Crystallization and X-Ray Data Analysis of the Extended Dna-Binding Domain of the E2 Bovine Papillomavirus Type 1 Protein
Protein & Peptide Letters Targeted Vascular Drug Delivery in Cerebral Cancer
Current Pharmaceutical Design